Innovate in Emerging Markets

Develop therapies in emerging markets and take these affordable solutions globally.

Prioritize Indications Prevalent in Emerging Markets with Global Potential : We prioritise high unmet indications prevalent in emerging markets with the potential to serve globally with successful transformative therapies. It helps us address needs not only in low-income countries but underserved population in developed countries who cannot afford expensive therapies.

Conduct Clinical Studies in Emerging Markets : The conventional pharmaceutical model involves innovating in developed markets for developed markets before expanding into emerging markets. However, the high cost of developing innovative therapies is often unaffordable in countries where out-of-pocket payments are the norm. To address this, we develop therapies in emerging markets with comparatively lower costs for discovery and clinical development and subsequently prioritise launching in these markets. Notably, there is currently a well-established clinical development infrastructure in emerging markets to support this approach.

Consider Parallel Pivotal Studies across Target Markets : We conduct initial discovery and development in India for proof-of-concept studies, but after POC, we conduct global clinical studies, including the required number of patients for bridging studies across target markets. This helps us reduce the development cost and accelerate parallel launches across these markets without significant lag so that all the patients across these countries get benefit.

Expand globally, including developed markets as affordable alternatives : All patients, even in developed countries, are not able to afford expensive therapies that incur significant out-of-pocket costs without insurance coverage. Following our success in emerging markets, we intend to introduce innovative solutions to developed markets as affordable alternatives for those in need.